NASDAQ : VRTX

Vertex Pharmaceuticals Incorporated

$477.36 USD

$4.27 (0.9%)

Volume
1.25M
Average Volume
1.52M
Market Capitalization
$121.16B
P/E Ratio
28.06
Dividend Yield
0.00%
Price Target
$576.00
Year High
$533.67
Year Low
$362.50
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$3.02
Company Overview

NASDAQ

Reshma Kewalramani

Biotechnology

Healthcare

VRTX

6400

US

USD

https://www.vrtx.com

617 341 6100

92532F100

0000875320

Liquidity Metrics

0.10

3.02

2.57

1.42

0.00

Sales & Valuation

$12.07B

9.89

6.26

32.65

14.60

Profitability

$15.32

$3.95B

35.40%

42.15%

23.93%

16.38%

P/E Metrics

28.06

0.05

0.05

Analyst Price Target & Rating

$576.00

$616.00

$350.00

Buy

4/5

56 Analysts

-17.13%

Financial Health Scores

12.35

5/9

$7.85B

$26.48B

$7.12B

$5.18B

Key Metrics (TTM)

$117.65B

9.60

21.82

3.02

23.93%

17.74%

3.58%

3.06%

$171.09

337 days

Company Executives
Name Title
Carmen Bozic Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer
Reshma Kewalramani FASN Chief Executive Officer, President & Director
Amit K. Sachdev Executive Vice President & Chief Patient and External Affairs Officer
Charles F. Wagner Jr. Executive Vice President, Chief Operating Officer & Chief Financial Officer
Jeffrey Marc Leiden Executive Chairman
Ourania Tatsis Executive Vice President and Chief Regulatory & Quality Officer
Kristen C. Ambrose Senior Vice President & Chief Accounting Officer
Mark Bunnage D.Phil Executive Vice President & Chief Scientific Officer
Joy Liu EVP, Chief Legal Officer & Corporate Secretary
Susie Lisa Senior Vice President of Investor Relations
Poll Results

No votes yet today — be the first to share your view!

About Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosc ... lerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.

Vertex Pharmaceuticals (VRTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

2026-07-22 18:51:11

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $472.57, marking a -1.96% move from the previous day.

ABN Amro Investment Solutions Grows Holdings in Vertex Pharmaceuticals Incorporated $VRTX

2026-07-22 05:39:13

ABN Amro Investment Solutions boosted its position in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 257.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 68,216 shares of the pharmaceutical company's stock after buying an additional 49,146 shares during the quarter.

Andra AP fonden Has $10.67 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX

2026-07-22 04:21:09

Andra AP fonden cut its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 33.5% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,903 shares of the pharmaceutical company's stock after selling 12,037 shares during the quarter. Andra

Amova Asset Management Americas Inc. Cuts Holdings in Vertex Pharmaceuticals Incorporated $VRTX

2026-07-22 03:44:10

Amova Asset Management Americas Inc. lowered its stake in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 66.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,115 shares of the pharmaceutical company's stock after selling 4,199 shares during the period. Amova

Why Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market Today

2026-07-20 19:01:05

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $480.5, denoting a -1.06% move from the preceding trading day.

Boston Common Asset Management LLC Has $7.68 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX

2026-07-20 05:08:45

Boston Common Asset Management LLC grew its position in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 7.0% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 17,205 shares of the pharmaceutical company's stock after purchasing an additional 1,124 shares

Broderick Brian C Purchases 1,454 Shares of Vertex Pharmaceuticals Incorporated $VRTX

2026-07-20 04:35:03

Broderick Brian C grew its position in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 8.5% in the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 18,656 shares of the pharmaceutical company's stock after buying an additional 1,454 shares during the period. Vertex Pharmaceuticals makes up about 1.5% of

Vertex Pharmaceuticals Just Made a $10 Billion Acquisition Worth Watching

2026-07-19 19:45:00

Vertex Pharmaceuticals' latest acquisition grants it access to products with $5 billion peak annual sales potential. The company's business is strong thanks to its dominance in its core market and new launches in other areas.

Frequently Asked Questions

What is the current Vertex Pharmaceuticals Incorporated (VRTX) stock price?

Vertex Pharmaceuticals Incorporated(NASDAQ:VRTX) stock price is $477.36 in the last trading session. During the trading session, VRTX stock reached the peak price of $533.67 while $362.5 was the lowest point it dropped to. The percentage change in VRTX stock occurred in the recent session was 0.9% while the dollar amount for the price change in VRTX stock was $4.27.

VRTX's industry and sector of operation?

The NASDAQ listed VRTX is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of VRTX?

Carmen Bozic | Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer
Reshma Kewalramani FASN | Chief Executive Officer, President & Director
Amit K. Sachdev | Executive Vice President & Chief Patient and External Affairs Officer
Charles F. Wagner Jr. | Executive Vice President, Chief Operating Officer & Chief Financial Officer
Jeffrey Marc Leiden | Executive Chairman

How many employees does VRTX have?

Number of VRTX employees currently stands at 6400. VRTX operates from 50 Northern Avenue, Boston, MA 02210, US.

Link for VRTX official website?

Official Website of VRTX is: https://www.vrtx.com

How do I contact VRTX?

VRTX could be contacted at phone #617 341 6100 and can also be accessed through its website. VRTX operates from 50 Northern Avenue, Boston, MA 02210, US.

How many shares of VRTX are traded daily?

The average number of VRTX shares traded daily for last 3 months was 1.52M.

What is the market cap of VRTX currently?

The market value of VRTX currently stands at $121.16B with its latest stock price at $477.36